Filtered By:
Countries: South Korea Health
This page shows you your search results in order of date. This is page number 17.
Order by Relevance | Date
Total 408 results found since Jan 2013.
Neurological Manifestations in Patients with COVID-19: Experiences from the Central Infectious Diseases Hospital in South Korea
CONCLUSIONS: Neurological manifestations were commonly observed in patients with COVID-19. During the current pandemic, when patients present with new-onset neurological symptoms, COVID-19 may be considered as part of the differential diagnosis. Attention to severe neurological complications is needed, especially in patients with severe or critical COVID-19.PMID:34184452 | PMC:PMC8242315 | DOI:10.3988/jcn.2021.17.3.435
Source: Journal of Clinical Neurology - June 29, 2021 Category: Neurology Authors: Hyun Kyung Kim Yeo Jeong Cho Seo Young Lee Source Type: research
Fimasartan-Based Blood Pressure Control after Acute Cerebral Ischemia: The Fimasartan-Based Blood Pressure Control after Acute Cerebral Ischemia Study
CONCLUSIONS: Fimasartan-based BP lowering achieved the target BP in two-thirds of patients at 24 weeks, and was generally well tolerated.PMID:34184441 | PMC:PMC8242309 | DOI:10.3988/jcn.2021.17.3.344
Source: Journal of Clinical Neurology - June 29, 2021 Category: Neurology Authors: Keun Sik Hong Sun Uck Kwon Jong Ho Park Jae Kwan Cha Jin Man Jung Yong Jae Kim Kyung Bok Lee Sung Il Sohn Yong Seok Lee Joung Ho Rha Jee Hyun Kwon Sang Won Han Bum Joon Kim Jaseong Koo Jay Chol Choi Sang Min Sung Soo Joo Lee Man Seok Park Seong Hwan Ahn O Source Type: research
Neurological Manifestations in Patients with COVID-19: Experiences from the Central Infectious Diseases Hospital in South Korea
CONCLUSIONS: Neurological manifestations were commonly observed in patients with COVID-19. During the current pandemic, when patients present with new-onset neurological symptoms, COVID-19 may be considered as part of the differential diagnosis. Attention to severe neurological complications is needed, especially in patients with severe or critical COVID-19.PMID:34184452 | PMC:PMC8242315 | DOI:10.3988/jcn.2021.17.3.435
Source: Journal of Clinical Neurology - June 29, 2021 Category: Neurology Authors: Hyun Kyung Kim Yeo Jeong Cho Seo Young Lee Source Type: research
Fimasartan-Based Blood Pressure Control after Acute Cerebral Ischemia: The Fimasartan-Based Blood Pressure Control after Acute Cerebral Ischemia Study
CONCLUSIONS: Fimasartan-based BP lowering achieved the target BP in two-thirds of patients at 24 weeks, and was generally well tolerated.PMID:34184441 | PMC:PMC8242309 | DOI:10.3988/jcn.2021.17.3.344
Source: Journal of Clinical Neurology - June 29, 2021 Category: Neurology Authors: Keun Sik Hong Sun Uck Kwon Jong Ho Park Jae Kwan Cha Jin Man Jung Yong Jae Kim Kyung Bok Lee Sung Il Sohn Yong Seok Lee Joung Ho Rha Jee Hyun Kwon Sang Won Han Bum Joon Kim Jaseong Koo Jay Chol Choi Sang Min Sung Soo Joo Lee Man Seok Park Seong Hwan Ahn O Source Type: research
Neurological Manifestations in Patients with COVID-19: Experiences from the Central Infectious Diseases Hospital in South Korea
CONCLUSIONS: Neurological manifestations were commonly observed in patients with COVID-19. During the current pandemic, when patients present with new-onset neurological symptoms, COVID-19 may be considered as part of the differential diagnosis. Attention to severe neurological complications is needed, especially in patients with severe or critical COVID-19.PMID:34184452 | PMC:PMC8242315 | DOI:10.3988/jcn.2021.17.3.435
Source: Journal of Clinical Neurology - June 29, 2021 Category: Neurology Authors: Hyun Kyung Kim Yeo Jeong Cho Seo Young Lee Source Type: research
Fimasartan-Based Blood Pressure Control after Acute Cerebral Ischemia: The Fimasartan-Based Blood Pressure Control after Acute Cerebral Ischemia Study
CONCLUSIONS: Fimasartan-based BP lowering achieved the target BP in two-thirds of patients at 24 weeks, and was generally well tolerated.PMID:34184441 | PMC:PMC8242309 | DOI:10.3988/jcn.2021.17.3.344
Source: Journal of Clinical Neurology - June 29, 2021 Category: Neurology Authors: Keun Sik Hong Sun Uck Kwon Jong Ho Park Jae Kwan Cha Jin Man Jung Yong Jae Kim Kyung Bok Lee Sung Il Sohn Yong Seok Lee Joung Ho Rha Jee Hyun Kwon Sang Won Han Bum Joon Kim Jaseong Koo Jay Chol Choi Sang Min Sung Soo Joo Lee Man Seok Park Seong Hwan Ahn O Source Type: research
Neurological Manifestations in Patients with COVID-19: Experiences from the Central Infectious Diseases Hospital in South Korea
CONCLUSIONS: Neurological manifestations were commonly observed in patients with COVID-19. During the current pandemic, when patients present with new-onset neurological symptoms, COVID-19 may be considered as part of the differential diagnosis. Attention to severe neurological complications is needed, especially in patients with severe or critical COVID-19.PMID:34184452 | PMC:PMC8242315 | DOI:10.3988/jcn.2021.17.3.435
Source: Journal of Clinical Neurology - June 29, 2021 Category: Neurology Authors: Hyun Kyung Kim Yeo Jeong Cho Seo Young Lee Source Type: research
Fimasartan-Based Blood Pressure Control after Acute Cerebral Ischemia: The Fimasartan-Based Blood Pressure Control after Acute Cerebral Ischemia Study
CONCLUSIONS: Fimasartan-based BP lowering achieved the target BP in two-thirds of patients at 24 weeks, and was generally well tolerated.PMID:34184441 | PMC:PMC8242309 | DOI:10.3988/jcn.2021.17.3.344
Source: Journal of Clinical Neurology - June 29, 2021 Category: Neurology Authors: Keun Sik Hong Sun Uck Kwon Jong Ho Park Jae Kwan Cha Jin Man Jung Yong Jae Kim Kyung Bok Lee Sung Il Sohn Yong Seok Lee Joung Ho Rha Jee Hyun Kwon Sang Won Han Bum Joon Kim Jaseong Koo Jay Chol Choi Sang Min Sung Soo Joo Lee Man Seok Park Seong Hwan Ahn O Source Type: research
Neurological Manifestations in Patients with COVID-19: Experiences from the Central Infectious Diseases Hospital in South Korea
CONCLUSIONS: Neurological manifestations were commonly observed in patients with COVID-19. During the current pandemic, when patients present with new-onset neurological symptoms, COVID-19 may be considered as part of the differential diagnosis. Attention to severe neurological complications is needed, especially in patients with severe or critical COVID-19.PMID:34184452 | PMC:PMC8242315 | DOI:10.3988/jcn.2021.17.3.435
Source: Journal of Clinical Neurology - June 29, 2021 Category: Neurology Authors: Hyun Kyung Kim Yeo Jeong Cho Seo Young Lee Source Type: research
Fimasartan-Based Blood Pressure Control after Acute Cerebral Ischemia: The Fimasartan-Based Blood Pressure Control after Acute Cerebral Ischemia Study
CONCLUSIONS: Fimasartan-based BP lowering achieved the target BP in two-thirds of patients at 24 weeks, and was generally well tolerated.PMID:34184441 | PMC:PMC8242309 | DOI:10.3988/jcn.2021.17.3.344
Source: Journal of Clinical Neurology - June 29, 2021 Category: Neurology Authors: Keun Sik Hong Sun Uck Kwon Jong Ho Park Jae Kwan Cha Jin Man Jung Yong Jae Kim Kyung Bok Lee Sung Il Sohn Yong Seok Lee Joung Ho Rha Jee Hyun Kwon Sang Won Han Bum Joon Kim Jaseong Koo Jay Chol Choi Sang Min Sung Soo Joo Lee Man Seok Park Seong Hwan Ahn O Source Type: research
Neurological Manifestations in Patients with COVID-19: Experiences from the Central Infectious Diseases Hospital in South Korea
CONCLUSIONS: Neurological manifestations were commonly observed in patients with COVID-19. During the current pandemic, when patients present with new-onset neurological symptoms, COVID-19 may be considered as part of the differential diagnosis. Attention to severe neurological complications is needed, especially in patients with severe or critical COVID-19.PMID:34184452 | PMC:PMC8242315 | DOI:10.3988/jcn.2021.17.3.435
Source: Journal of Clinical Neurology - June 29, 2021 Category: Neurology Authors: Hyun Kyung Kim Yeo Jeong Cho Seo Young Lee Source Type: research
Fimasartan-Based Blood Pressure Control after Acute Cerebral Ischemia: The Fimasartan-Based Blood Pressure Control after Acute Cerebral Ischemia Study
CONCLUSIONS: Fimasartan-based BP lowering achieved the target BP in two-thirds of patients at 24 weeks, and was generally well tolerated.PMID:34184441 | PMC:PMC8242309 | DOI:10.3988/jcn.2021.17.3.344
Source: Journal of Clinical Neurology - June 29, 2021 Category: Neurology Authors: Keun Sik Hong Sun Uck Kwon Jong Ho Park Jae Kwan Cha Jin Man Jung Yong Jae Kim Kyung Bok Lee Sung Il Sohn Yong Seok Lee Joung Ho Rha Jee Hyun Kwon Sang Won Han Bum Joon Kim Jaseong Koo Jay Chol Choi Sang Min Sung Soo Joo Lee Man Seok Park Seong Hwan Ahn O Source Type: research
